目的 探討香砂六君丸聯(lián)合莫沙必利治療功能性消化不良的臨床療效。方法 選取2020年11月—2023年12月資陽市精神病醫(yī)院收治的104例功能性消化不良患者，按隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各52例。對(duì)照組飯前口服枸櫞酸莫沙必利片，1片/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服香砂六君丸，6 g/次，3次/d。兩組療程均為4周。觀察兩組臨床療效，比較治療前后兩組主癥積分、胃排空指標(biāo)、癥狀自評(píng)量表（SCL-90）、功能性消化不良生存質(zhì)量量表（FDDQL）評(píng)分及血清胃動(dòng)素（MTL）、生長(zhǎng)抑素（SS）、胃泌素（Gas）、降鈣素基因相關(guān)肽（CGRP）水平。結(jié)果 治療組總有效率96.15%顯著高于對(duì)照組的84.62%（P＜0.05）。治療后兩組餐后飽脹不適積分、早飽感積分、中上腹燒灼感積分、中上腹痛積分均顯著降低（P＜0.05）；治療后，治療組主癥積分低于對(duì)照組（P＜0.05）。治療后，兩組胃竇收縮頻率顯著增高，而2 h胃殘留率顯著降低，胃半排空時(shí)間都顯著縮短（P＜0.05）；治療后，治療組胃竇收縮頻率高于對(duì)照組，2 h胃殘留率和胃半排空時(shí)間低于對(duì)照組（P＜0.05）。治療后，兩組SCL-90評(píng)分都顯著降低，F(xiàn)DDQL評(píng)分都顯著增高（P＜0.05）；治療后，治療組SCL-90評(píng)分低于對(duì)照組，F(xiàn)DDQL評(píng)分高于對(duì)照組（P＜0.05）。治療后，兩組血清MTL水平都顯著上升，血清SS、Gas、CGRP水平均降低（P＜0.05）；治療后，治療組MTL水平高于對(duì)照組，血清SS、Gas、CGRP水平低于對(duì)照組（P＜0.05）。結(jié)論 香砂六君丸聯(lián)合莫沙必利治療功能性消化不良能有效糾正患者胃腸激素失衡，促進(jìn)胃排空，減輕臨床癥狀，患者心理狀態(tài)及生活質(zhì)量可得到進(jìn)一步改善，值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Xiangsha Liujun Pills combined with mosapride in treatment of functional dyspepsia. Methods 104 Patients with functional dyspepsia admitted to Ziyang Psychiatric Hospital from November 2020 to December 2023 were divided into control group and treatment group by random number table method, with 52 cases in each group. Patients in control group were po administered with Mosapride Citrate Tablets, 1 tablet/time, three times daily. Patients in treatment group were po administered with Xiangsha Liujun Pills on the basis of the control group, 6 g/time, 3 times daily. The treatment course of both groups was 4 weeks. The clinical efficacy of two groups was observed, and the scores of major symptoms, gastric emptying index, Symptom self-rating Scale (SCL-90), functional dyspeptic Quality of Life Scale (FDDQL) and serum levels of motilin (MTL), somatostatin (SS), gastrin (Gas) and calcitonin gene-related peptide (CGRP) were compared before and after treatment. Results The total effective rate (96.15%) in treatment group was significantly higher than 84.62% in control group (P < 0.05). After treatment, the scores of fullness and discomfort, the scores of early satiety, the scores of burning sensation in middle and upper abdomen, and the scores of middle and upper abdominal pain were significantly decreased in both groups (P < 0.05). After treatment, the score of major symptoms in treatment group was lower than that in control group (P < 0.05). After treatment, the frequency of gastric antrum contraction was significantly increased, the gastric residual rate at 2 h was significantly decreased, and the gastric half-empty time was significantly shortened in both groups (P < 0.05). After treatment, the frequency of gastric antrum contraction in the treatment group was higher than that in the control group, and the gastric residual rate and half-empty time at 2 h were lower than those in the control group (P < 0.05). After treatment, SCL-90 score was significantly decreased in both groups, but FDDQL score was significantly increased in both groups (P < 0.05). After treatment, the SCL-90 score of the treatment group was lower than that of the control group, but the FDDQL score was higher than that of the control group (P < 0.05). After treatment, serum MTL levels were significantly increased in both groups, but serum SS, Gas and CGRP levels were decreased (P < 0.05). After treatment, the levels of MTL in treatment group were higher than those in control group, but the serum levels of SS, Gas and CGRP were lower than those in control group (P < 0.05). Conclusion The combination of Xiangsha Liujun Pills and Mosapride can effectively correct the imbalance of gastrointestinal hormones in patients with functional dyspepsia, and can promotie gastric emptying, alleviating clinical symptoms, and further improving patients’ psychological state and quality of life, which is worthy of clinical application.

R975

資陽市醫(yī)學(xué)科學(xué)課題項(xiàng)目（KY2023086）